US will still pay at least twice as much after negotiating drug prices
U.S. pays higher drug prices, gets priority access
Medicare's negotiated prices most significant for drugs with little competition
Goal is to balance affordability and innovation
Updates first graphic to align colors representing countries with second graphic
By Deena Beasley
Sept 3 (Reuters) -The U.S. government's first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income countries, a Reuters review has found.
The U.S. Medicare health plan, which covers more than 67 million people, recently unveiled new maximum prices for the first 10 high-cost medicines negotiated under the Biden Administration's Inflation Reduction Act.
This is the first time Medicare has disclosed actual drug prices, which are largely hidden behind a complicated U.S. system of rebates and discounts. The lower prices will result in savings of $6 billion in 2026, the first year they take effect, Medicare said.
A Reuters review of publicly available maximum prices set by other wealthy nations - Australia, Japan, Canada and Sweden - show that they have negotiated far lower prices for the same drugs.
A 30-day supply of nine of the 10 drugs will cost $17,581 for Medicare in 2026, compared with $6,725 in Sweden this year. Comparable prices were not available for the 10th drug, Novo Nordisk's NOVOb.CO insulin Novolog.
"In the U.S. we've always accepted that we are the country that overpays relative to the rest of the world," said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University.
The U.S. sees value in being the preferred customer, she said, pointing to early availability of COVID vaccines as an example of that advantage.
Many countries have universal prescription drug coverage that relies on centralized price negotiation with manufacturers, but U.S. law previously prevented Medicare - the nation's single biggest government program - from doing so.
Bristol Myers BMY.N said pricing was country specific and depended on national health systems and their regulatory policies, while Merck MRK.N said it was not valid to compare U.S. prices to overseas generics. Amgen AMGN.O declined to comment and the others drugmakers did not respond.
A spokesperson for the U.S. agency that oversees Medicare said the new law requires consideration of factors such as manufacturer data and availability of alternative treatments, but Congress did not include review of international prices in the negotiations.
U.S. ALWAYS PAYS MORE
A study by the non-profit RAND Corp looking at 2022 prescription prices found that U.S. health plans paid more than three times as much for brand-name pharmaceuticals, even after estimated discounts.
Studies have shown that faster uptake of new and more expensive drugs helps drive U.S. prices, while other high-income countries directly footing the bill for healthcare place tighter restrictions on prescriptions.
The willingness of the U.S. to pay up for drugs also contributes to lower overseas prices, said Richard Frank, director of the Brookings Institution's Center on Health Policy.
"If you've got one of your buyers who's willing to cover your sunk costs, plus some of your ongoing costs," selling more volume to others, even at lower prices, can still be profitable, he said.
In some cases, lower-cost generic or biosimilar versions of the original branded drugs are already available outside the U.S. Generic versions of Merck's Januvia, for instance, have been on the market in Canada since late 2022, while U.S. patents for the diabetes drug are in place until 2026.
Once patents expire on a brand-name drug and copycat versions hit the market, prices fall sharply. But drugmakers are often able to extend U.S. patent coverage by making small changes to things like dosage or formulation.
There are still no U.S. biosimilar competitors for one of the most expensive of the negotiated drugs, Amgen's Enbrel, which was first approved in 1998 for rheumatoid arthritis. U.S. courts have upheld Amgen's patents, blocking biosimilars until 2029.
Other countries already have multiple options. Sweden's price for a 30-day supply of an Enbrel biosimilar is $709, compared with Medicare's newly-negotiated price of $2,355.
Since most drugmakers hike U.S. prices annually, "the longer a drug is in the U.S. market, the more we pay," said Mariana Socal, associate scientist at Johns Hopkins Bloomberg School of Public Health, noting that in other countries prices typically come down over time.
An analysis by the Brookings Institution showed that Medicare's negotiations yielded the biggest benefit for drugs with little market competition. It found that three drugs - Enbrel, Bristol Myers' and Pfizer's PFE.N blood thinner Eliquis, and Johnson & Johnson's JNJ.N Crohn's disease drug Stelara - will account for more than half of Medicare's expected $6 billion savings.
Even for the medicines with no generic competition outside the U.S., other governments have set lower prices.
The most Medicare agreed to pay for AstraZeneca's AZN.L diabetes drug Farxiga is $179 for a 30-day supply. Sweden's maximum price for 30 days of Farxiga's standard dose is $35, and the price in Canada is about $60.
Each year, more drugs will be up for price negotiation by Medicare, which accounts for about a third of U.S. drug spending.
"We're going to see the U.S. pushing the market ... so that the U.S. pays something that sort of does a better job of balancing affordability, innovation, and incentives," Brookings' Frank said.
Prices for drugs included in U.S. Medicare's first negotiations 2 https://reut.rs/3MrxHZ6
Prices for drugs included in U.S. Medicare's first negotiations Prices for drugs included in U.S. Medicare's first negotiations https://reut.rs/4e704r1
Reporting By Deena Beasley in Los Angeles; Additional reporting by Patrick Wingrove in New York; Editing by Caroline Humer and Bill Berkrot
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
